• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

1.82 EUR-1.84 %10.7. klo 18.29
2,225 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.84 %
+3.53 %
+4.37 %
-22.06 %
-27.07 %
-45.14 %
-58.63 %
-
-64.11 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
67.89M EUR
Turnover
65.37K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
09.03.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
https://partner.microsoft.com/en-my/case-studies/aiforia-ai-assisted-pathology-nhs A little bit of a blog post for you. Experiences with Aiforia from the University Hospital Southampton NHS Foundation Trust.
7/8/2026, 1:33 PM
by Jekkku
17
TJ Tenkanen has been shopping again on Friday; the previous trades were made a week earlier. I’m starting to give some weight to these voluntary management acquisitions; with experience, it’s beginning to become a red flag for me if this doesn’t happen (Sosi, Optomed, BBS…). HOWEVER...
7/6/2026, 6:30 AM
by Akkanen
16
Has anyone here looked into ArteraAI? Personalized Precision Medicine & AI Cancer Therapy | ArteraAI. As a U.S.-based company, it seems to have gained a strong foothold in the States, and their board includes some very big names (e.g., Lip-Bu Tan, the current CEO of Intel, and Marc...
7/10/2026, 5:53 AM
12
If I had to guess, Lundin probably already has his next startup in the works. It’s likely a good idea to set aside capital for it now that Aiforia is up and running. It’s worth watching the video linked here earlier, which features a lecture by Lundin on the subject. He talks specifically...
7/6/2026, 8:17 AM
by jerej
11
aiforia.com Join Aiforia's partner network Aiforia’s network of partners ensures that our customers in clinical, pre-clinical, and academic labs can choose the technologies and enjoy the full benefits of a digitized workflow with seamless integrations into their existing laboratory...
7/5/2026, 4:54 AM
by Salvelinus
9
The situation in the UK is actually quite interesting. Aiforia won that 3-year framework agreement with a consortium of 25 hospitals in February 2023 Aiforia receives a contract award to provide AI solutions for 25 NHS hospitals of the PathLAKE Plus consortium in the UK, but there...
7/10/2026, 5:34 AM
8
Could that first batch sold by Lundin have gone to Tenkanen? The quantity and price are at least the same.
7/6/2026, 6:48 AM
by Salvelinus
8
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8.
2026

Interim report Q2'26

Regulatory press release06.07.2026 klo 09.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release06.07.2026 klo 09.00

Aiforia Technologies Plc – Managers’ Transactions – Johan Lundin

Aiforia Technologies
Regulatory press release01.07.2026 klo 21.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Acme Investments SPF Sarl)

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Third party research29.06.2026 klo 10.21

Aiforia Technologies: € 6.4m share issue de-risks the investment case - NuWays AG Research

On Thursday evening, Aiforia announced having completed a directed share issue of 3.6m shares at € 1.772 per share, raising gross proceeds of some € 6.4m. The subscription price corresponds to the closing price of June 25th, representing no discount ...

Aiforia Technologies
Regulatory press release26.06.2026 klo 16.30

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release26.06.2026 klo 16.20

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Tuomas Tenkanen/TJT Technologies Oy)

Aiforia Technologies
Regulatory press release26.06.2026 klo 12.15

A total of 3,600,000 new shares in Aiforia Technologies Plc registered with the Trade Register

Aiforia Technologies
Aiforia collects 6.4 MEUR in a directed share issue
Analyst Comment26.06.2026 klo 08.49 by
Antti Siltanen

Aiforia collects 6.4 MEUR in a directed share issue

The company's financial risk in the coming years will diminish if the planned EIB loan materializes in addition to the share issue.

Aiforia Technologies
Regulatory press release25.06.2026 klo 22.00

Inside information: Aiforia Technologies Plc successfully completes a directed share issue raising approximately EUR 6.4 million

Aiforia Technologies
Regulatory press release25.06.2026 klo 18.31

Inside information: Aiforia Technologies Plc intends to carry out a directed share issue by means of an accelerated bookbuilding process

Aiforia Technologies
Third party research17.06.2026 klo 09.21

Aiforia Technologies: €20m EIB debt term sheet de-risks Aiforia's funding outlook - NuWays AG Research

Aiforia agrees non-binding EIB term sheet for up to €20m venture debt, materially de-risking the funding outlook. BUY, PT €3.80 unchanged.

Aiforia Technologies
Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB
Analyst Comment16.06.2026 klo 09.16 by
Antti Siltanen, Antti Luiro

Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB

The financing package would significantly reduce the short-term financing risk.

Aiforia Technologies
Regulatory press release15.06.2026 klo 21.45

Inside information: Aiforia and the European Investment Bank agree upon a non-binding indicative term sheet for an up to EUR 20 million venture debt financing facility

Aiforia Technologies
Aiforia expands to nine hospitals in Spain
Analyst Comment12.06.2026 klo 09.26 by
Antti Siltanen

Aiforia expands to nine hospitals in Spain

The news continues Aiforia's series of gradual growth steps with 9 new hospitals.

Aiforia Technologies
Press release11.06.2026 klo 09.30

Aiforia expands its presence in Spain through a new clinical account

Aiforia Technologies
Regulatory press release18.05.2026 klo 17.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act - Mikko Laakkonen’s holding in Aiforia Technologies Plc

Aiforia Technologies
M&A activity in digital pathology is increasing
Analyst Comment15.05.2026 klo 09.45 by
Antti Siltanen, Antti Luiro

M&A activity in digital pathology is increasing

Consolidation has occurred in Aiforia's industry over the past 12–18 months.

Aiforia Technologies
Regulatory press release12.05.2026 klo 13.00

Resolutions of Aiforia Technologies Plc’s Extraordinary General Meeting 2026

Aiforia Technologies
Third party research11.05.2026 klo 10.18

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)

(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection...

Aiforia Technologies
Third party research11.05.2026 klo 09.12

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research

Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection with the deal...

Aiforia Technologies